Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Zanubrutinib Plus Rituximab as Front-line Treatment for Mucosa-associated Lymphoid Tissue Lymphoma (MALT): a Single-arm, Open-label, Multicenter, Phase II Study（ZAMA）

NCT06647732 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.

NCT NCT06647732
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06647732 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Zanubrutinib Plus Rituximab as Front-line Treatment for Mucosa-associated Lymphoid Tissue Lymphoma (MALT): a Single-arm, Open-label, Multicenter, Phase II Study（ZAMA）
Lead sponsor
Sun Yat-sen University
Phase
Phase 2
Overall status
Active, not recruiting
Start date
October 30, 2024
Completion date
September 30, 2028
Enrollment
42 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

mucosa-associated lymphoid tissue lymphoma (malt)